A Multimethod Evaluation to Assess Feasibility, Acceptability, and Preliminary Efficacy of HPVVaxFacts, a Tailored Mobile Web App, for Parents With Unvaccinated Children: Pilot 2-Arm Randomized Controlled Trial.

JMIR CancerSep 9, 2026 (epub)
Clinical ResearchPediatricsPreventive Medicine / Public Health

Jennifer Cunningham-Erves, Pamela C Hull, Amanda F Dempsey et al.

✦ AI-curated · Sources linked

In 30 seconds

This pilot randomized controlled trial evaluated the feasibility, acceptability, and preliminary efficacy of HPVVaxFacts, a mobile web app designed for parents of unvaccinated adolescents aged 9-17. Conducted in urban Tennessee clinics, the study found that HPV vaccine initiation was significantly higher in the intervention group (48%) compared to the control group (17%; P =.01).

Key findings

  • HPV vaccine initiation was 48% in the intervention group versus 17% in the control group (P =.01).
  • Parents in the HPVVaxFacts arm showed a greater reduction in concern scores compared to the control group (mean change: -3.4 vs -1.4).
  • 81% of parents viewed the HPVVaxFacts app.
  • The majority of participants found the study protocol and HPVVaxFacts acceptable.

Why it matters

Improving communication and education about HPV vaccination through mobile health interventions may enhance vaccination rates among adolescents, addressing public health concerns regarding HPV-related diseases.

Source

PubMed · PMID 42715554

Published in JMIR Cancer. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.